Journal article
A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177
Abstract
Background:AT7519 is a small-molecular inhibitor of multiple cyclin-dependent kinases (CDKs). It shows encouraging anti-cancer activity against multiple cell lines and in tumour xenografts. This phase I study was conducted to evaluate the safety and tolerability of AT7519 given as 1-h intravenous infusion on days 1, 4, 8 and 11 every 3 weeks.Methods:Patients with advanced refractory solid tumours or non-Hodgkin’s lymphoma were enroled. Dose …
Authors
Chen EX; Hotte S; Hirte H; Siu LL; Lyons J; Squires M; Lovell S; Turner S; McIntosh L; Seymour L
Journal
British Journal of Cancer, Vol. 111, No. 12, pp. 2262–2267
Publisher
Springer Nature
Publication Date
December 2014
DOI
10.1038/bjc.2014.565
ISSN
0007-0920